Category

Strategic Advisors
ISPOR EU 2023 in Copenhagen

ISPOR EU 2023 in Copenhagen

This year’s theme was “HEOR at the Nexus of Policy and Science” and, as with ISPOR in Boston in May, the real-world evidence (RWE) discussions largely focused on the use and acceptance of real-world data (RWD) in regulatory/reimbursement submissions.

Pathways to early access in oncology

Pathways to early access in oncology

The pressure on payers to offer patients timely access to life-saving oncology medicines has increased with the rapid development of innovative treatments. Balancing the urgency to provide access with the need for evidence-based decision-making from phase III trials presents a significant challenge to publicly funded systems worldwide.

Cardiology trends during the COVID-19 pandemic

Cardiology trends during the COVID-19 pandemic

The COVID-19 pandemic had profound impacts on healthcare systems and patients around the world. Systems faced unprecedented challenges including resource reallocation, overwhelmed hospitals, and disruptions in routine care. Retrospective studies are now assessing the long-term cumulative effects of the pandemic and associated public health measures.

Methods Matter: Adjusting for the Wrong Covariates Can Introduce Bias Instead of Correcting it

Methods Matter: Adjusting for the Wrong Covariates Can Introduce Bias Instead of Correcting it

Causal diagrams such as directed acyclic graphs (DAGs) can help in identifying a minimum set of confounding variables that need to be adjusted for. Arbitrarily dumping every available variable into a regression model can lead to biased estimates and incorrect conclusions about the effectiveness of a health intervention, its safety profile, and its downstream effects.

CADTH Symposium 2023: Is Canada Ready?

CADTH Symposium 2023: Is Canada Ready?

Medlior’s Founder and President Tara Cowling was delighted to attend the CADTH Symposium 2023 in Ottawa last week. On the heels of the ISPOR 2023 conference, CADTH also tackled some key issues surrounding the use of RWE to inform decision-making.

2022: A Year in Review

2022: A Year in Review

As we slowly emerged from our COVID caves of 2020-2021, this year brought great excitement to Medlior.  We helped industry bring life-changing innovations to market, and we increased our stakeholder collaboration.